Author(s)

Lijuan Weng ¹, Qianyun Xie ², Ruishuang Ma ²

Affiliation(s)

¹ Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China
² Department of Radiotherapy and Chemotherapy, Ningbo First Hospital Zhejiang University Ningbo Hospital, Ningbo, China

Corresponding Author

Ruishuang Ma

ABSTRACT

Cancer immunotherapy has shown promising results in triple-negative breast cancer (TNBC), however, only a small proportion of patients benefit from the immune checkpoint inhibitors (ICI). To explore robust biomarkers to predict the prognosis of TNBC patients is in great need. In this study, we first established an immune risk scoring signature with the Cancer Genome Atlas (TCGA) database. The GO and KEGG enrichment were used for cluster analysis. The KM curve was performed for prognosis. The differentially expressed immune genes were  obtained for univariate and multivariate Cox and Lasso regression analysis, and 18 independent immune genes associated with prognosis were obtained to establish an immune risk score signature (IRSS). The Kaplan-Meier results showed that the prognosis of the high-risk group was significantly favorable than that of the low-risk group (P < 0.001; HR = 3.06, 95% CI = 2.16-4.32). The 18 targeted immune genes were enriched in JAK-STAT signaling pathway and IFNG was the most focus gene in TNBC compared with Luminal A/B and HER2 subtypes. Furthermore, TNBC patients with high level of both IFNG and checkpoints (CD274, PD-1, CTLA-4 and TIGHT) would have longer survival and IFNG was positively relevant to various checkpoints, especially PD-1/PD-L1. Taken together, our results indicate that dispite of the complicated effects of IFNG in immune microenvironment, IFNG is associated with better prognosis in TNBC and may act as a biomarker guiding the ICI therapy.

KEYWORDS

Triple-negative breast cancer, IFNG, Prognostic biomarker, Immune checkpoint blockade

CITE THIS PAPER

Lijuan Weng, Qianyun Xie, Ruishuang Ma, IFN-γ: a beneficial immune marker in triple-negative breast cancer. MEDS Clinical Medicine (2025) Vol. 6: 127-138. DOI: http://dx.doi.org/10.23977/medsc.2025.060118.

REFERENCES

[1] Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91-113. 
[2] Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485-1505.
[3] Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2020;18(4):479-489. 
[4] So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharmacol Ther. 2022;237:108253.
[5] Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-690. 
[6] Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell. 2018;173(2):530.
[7] Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2-3):234-239. 
[8] Jézéquel P, Gouraud W, Ben Azzouz F, Guérin-Charbonnel C, Juin PP, Lasla H, et al. bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database (Oxford). 2021;2021:baab007.
[9] Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, et al. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci. 2020;16(13):2430-2441. 
[10] Zhu C, Xia Q, Gu B, Cui M, Zhang X, Yan W, et al. Esophageal Cancer Associated Immune Genes as Biomarkers for Predicting Outcome in Upper Gastrointestinal Tumors. Front Genet. 2021;12:707299.
[11] Yue T, Cai Y, Zhu J, Liu Y, Chen S, Wang P, Rong L. Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients. Front Immunol. 2023;14:1064704. 
[12] Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud W, et al. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res. 2019;21(1):65.
[13] Cai B, Liu Y, Chong Y, Zhang H, Matsunaga A, Fang X, et al. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies. Mol Cancer. 2021;20(1):165. 
[14] Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
[15] Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820-832. 
[16] Huang J, Chen P, Liu K, Liu J, Zhou B, Wu R, et al. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut. 2021;70(5):890-899.
[17] Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178(4):933-948.e14. 
[18] Sorrentino C, D'Antonio L, Fieni C, Ciummo SL, Di Carlo E. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol. 2021;12:778329. 

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine